Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC

  • End date
    Mar 15, 2025
  • participants needed
  • sponsor
    Fudan University
Updated on 5 June 2022
measurable disease
advanced breast cancer
stage iv breast cancer
locally advanced breast cancer


To evaluate the efficacy and safety of sintilimab and bevacizumab biosimilar combined with pegylated liposomal doxorubicin in pretreated metastatic triple-negative breast cancer

Condition Breast Cancer
Treatment Pegylated Liposomal Doxorubicin, Sintilimab, Bevacizumab Biosimilar
Clinical Study IdentifierNCT05386524
SponsorFudan University
Last Modified on5 June 2022


Yes No Not Sure

Inclusion Criteria

Patients aged 18-70 years old
Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer
ER and PR negative, HER2 negative breast cancer
Received one or two lines of systemic treatment in metastatic setting
Measurable disease based on RECIST 1.1
ECOG Performance Status 0-1
Adequate hematological, renal and hepatic function according to all of the following laboratory values

Exclusion Criteria

Has received any prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received any prior therapy with bevacizumab
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent)
Has a known additional malignancy that is progressing or has required active treatment within the past 5 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, cervical cancer in situ) that have undergone potentially curative therapy
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Has a known history of hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipient
Has an active autoimmune disease that has required systemic treatment
Has a history of (non-infectious) pneumonitis that required treatment with steroids; or current pneumonitis
Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
Has been pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 180 days after the last dose of trial treatment
Failure to comply with the study procedures, restrictions and requirements of the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note